MX2009003912A - Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas. - Google Patents

Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.

Info

Publication number
MX2009003912A
MX2009003912A MX2009003912A MX2009003912A MX2009003912A MX 2009003912 A MX2009003912 A MX 2009003912A MX 2009003912 A MX2009003912 A MX 2009003912A MX 2009003912 A MX2009003912 A MX 2009003912A MX 2009003912 A MX2009003912 A MX 2009003912A
Authority
MX
Mexico
Prior art keywords
spirochete
methods
compositions
management
treatment
Prior art date
Application number
MX2009003912A
Other languages
English (en)
Inventor
Jennifer L Hensel
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2009003912A publication Critical patent/MX2009003912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

Se describen métodos para tratar, prevenir y/o manejar una enfermedad o rastorno bacteriano por espiroqueta y/o bacteria intracelular obligada. Los métodos específicos abarcan la administración de un compuesto inmunomodulador solo o en combinación con un segundo agente activo.
MX2009003912A 2006-10-19 2007-10-19 Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas. MX2009003912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85284606P 2006-10-19 2006-10-19
PCT/US2007/022388 WO2008057196A2 (en) 2006-10-19 2007-10-19 Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases

Publications (1)

Publication Number Publication Date
MX2009003912A true MX2009003912A (es) 2009-05-11

Family

ID=39364972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003912A MX2009003912A (es) 2006-10-19 2007-10-19 Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.

Country Status (8)

Country Link
US (1) US20110184025A1 (es)
EP (1) EP2081561A2 (es)
JP (1) JP2010506937A (es)
CN (1) CN101557806A (es)
AP (1) AP2009004834A0 (es)
CA (1) CA2665778A1 (es)
MX (1) MX2009003912A (es)
WO (1) WO2008057196A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8405379B1 (en) 2008-09-18 2013-03-26 Luc Montagnier System and method for the analysis of DNA sequences in biological fluids
US8257938B2 (en) * 2009-02-27 2012-09-04 Medical Diagnostic Laboratories, Llc Hemolysin and its protein fragments in sero-detection of Anaplasma phagocytophilum
RS58523B1 (sr) 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
US20140228455A1 (en) * 2011-09-07 2014-08-14 Alpha Biotech Ab Determination of bacterial infections of the genus rickettsia and possibly borrelia, in patients exhibiting symptoms of disease and being blood donors
WO2013113000A2 (en) * 2012-01-26 2013-08-01 Luc Montagnier Detection of dna sequences as risk factors for hiv infection
JP6469077B2 (ja) 2013-04-02 2019-02-13 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP4242651B2 (ja) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
US7153867B2 (en) * 2001-08-06 2006-12-26 Celgene Corporation Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
KR20050057672A (ko) * 2002-10-24 2005-06-16 셀진 코포레이션 통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
WO2008057196A2 (en) 2008-05-15
US20110184025A1 (en) 2011-07-28
EP2081561A2 (en) 2009-07-29
AP2009004834A0 (en) 2009-04-30
CN101557806A (zh) 2009-10-14
CA2665778A1 (en) 2008-05-15
JP2010506937A (ja) 2010-03-04
WO2008057196A3 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
MX2009003912A (es) Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2012027065A3 (en) Combination therapy for treatment of disease
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
TW200718689A (en) 2-Amino-quinazolin-5-ones
GB2467670A (en) Chemical entities and therapeutic uses thereof
ZA200701629B (en) Gyrase inhibitors and uses thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TW200716628A (en) Novel compounds
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2010001574A (es) Ligandos del receptor cannabinoide.
BRPI0916885B8 (pt) composição farmacêutica
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal